INCIDENCE OF NEUROPATHY IN PATIENTS TREATED WITH SUBCUTANEOUS BORTEZOMIB

被引：0
|
作者：
Vicent Castello, A. [1 ]
Pellise Guinjoan, A. [2 ]
Escoda Teigell, L. [1 ]
Casanova Molla, J. [2 ]
Pascual Rubio, V [2 ]
Talarn Forcadell, C. [1 ]
Do Nascimento, J. [1 ]
Vallansot, R. [1 ]
Aguinaco Culebras, R. [1 ]
Gimenez Perez, T. [1 ]
Araguas Arasanz, C. [1 ]
Bru Orobal, N. [1 ]
Esteban Figuerola, A. [1 ]
Sarra Escarre, J. [1 ]
机构：
[1] ICO Tarragona, Tarragona, Spain
[2] Hosp Univ Joan XXIII Tarragona, Tarragona, Spain
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PC-092
引用
收藏
页码：113 / 114
页数：2
相关论文
共 50 条
  • [21] Neurologic Monitoring Reduces the Incidence of Bortezomib-Induced Peripheral Neuropathy in MM
    Petit, J.
    Velasco, R.
    Clapes, V.
    Bruna, J.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S25 - S26
  • [22] Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib
    Ling Peng
    Xianghua Ye
    Yun Zhou
    Junyan Zhang
    Qiong Zhao
    Supportive Care in Cancer, 2015, 23 : 2813 - 2824
  • [23] Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib
    Peng, Ling
    Ye, Xianghua
    Zhou, Yun
    Zhang, Junyan
    Zhao, Qiong
    SUPPORTIVE CARE IN CANCER, 2015, 23 (09) : 2813 - 2824
  • [24] UNEVENTFUL PREGNANCIES IN MULTIFOCAL MOTOR NEUROPATHY TREATED WITH SUBCUTANEOUS IMMUNOGLOBULINS
    Cocito, D.
    Paolasso, I
    Lopiano, L.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2013, 18 : 8 - 8
  • [25] COMPARISON OF FOUR NEUROPATHY ASSESSMENT SCALES IN EVALUATION OF TREATMENT EMERGENT NEUROPATHY IN NEWLY DIAGNOSED PATIENTS OF MULTIPLE MYELOMA TREATED WITH BORTEZOMIB BASED REGIMEN
    Lakshman, A.
    Prakash, G.
    Modi, M.
    Malhotra, P.
    Nampoothiri, R.
    Khadwal, A.
    Suri, V.
    Jain, S.
    Kumari, S.
    Varma, N.
    Varma, S.
    HAEMATOLOGICA, 2016, 101 : 533 - 533
  • [26] Peripheral Neuropathy Symptoms, Pain and Functioning in Relapsed or Refractory Multiple Myeloma Patients Treated with Selinexor, Bortezomib, and Dexamethasone
    Sanchez, Larysa
    Leleu, Xavier
    Beaumont, Jennifer
    Yu, Hailin
    Hudgens, Stacie
    Auner, Holger W.
    Quach, Hang
    Delimpasi, Sosana
    Spicka, Ivan
    Pour, Ludek
    Dimopoulos, Meletios A.
    Pylypenko, Halyna
    Doronin, Vadim A.
    Usenko, Ganna
    Hajek, Roman
    Benjamin, Reuben
    Venner, Christopher P.
    Garg, Mamta
    Stevens, Don A.
    Jagannath, Sundar
    Moreau, Philippe
    Levy, Moshe
    Bahlis, Nizar J.
    Facon, Thierry
    Chai, Yi
    Ma, Xiwen
    Tang, Shijie
    Leong, Hoyee
    Shah, Jatin J.
    Shacham, Sharon
    Kauffman, Michael G.
    Richardson, Paul G.
    Grosicki, Sebastian
    BLOOD, 2020, 136
  • [27] RVD with weekly subcutaneous bortezomib minimizes neuropathy and maintains efficacy in a diverse multiple myeloma cohort
    Gill, Amitoj
    Jayswal, Rani
    Weiss, Heidi
    Rhodes, Jill
    Hegazi, Mohamed
    Herzig, Geoffrey
    Herzig, Roger
    Krem, Maxwell
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E210 - E210
  • [28] Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis
    Sidana, Surbhi
    Narkhede, Mayur
    Elson, Paul
    Hastings, Debbie
    Faiman, Beth
    Valent, Jason
    Samaras, Christy
    Hamilton, Kimberly
    Liu, Hien K.
    Smith, Mitchell R.
    Reu, Frederic J.
    PLOS ONE, 2017, 12 (03):
  • [29] An Acceptable Incidence of Infusion Site Reactions after Subcutaneous Bortezomib Administration in the Upper Arm in Japanese Patients with Multiple Myeloma
    Ohgiya, Daisuke
    Tsuchiya, Takahide
    Suyama, Takahiro
    Watanabe, Shigeki
    Numata, Hiroki
    Tsuboi, Kosuke
    Sasao, Tamotsu
    ACTA HAEMATOLOGICA, 2015, 133 (01) : 29 - 30
  • [30] Impact of Body Mass Index on the Incidence of Bortezomib-induced Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma
    Moore, Donald C.
    Ringley, J. Tanner
    Nix, David
    Muslimani, Ala'a
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (03): : 168 - 173
12345